Thrombocythaemia and pregnancy

Best Practice and Research: Clinical Haematology

Volumn 16, Issue 2, 2003, Pages 227-242

  Elliott, Michelle A ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

Pregnancy; Thrombocythaemia; Thrombocytosis; Treatment; Young

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; HEPARIN; HYDROXYUREA; LOW MOLECULAR WEIGHT HEPARIN;

APHERESIS; BLEEDING; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG SAFETY; FEMALE; FETUS RISK; FIRST TRIMESTER PREGNANCY; HIGH RISK PREGNANCY; HUMAN; LEUKEMIA; MEDICAL INFORMATION; MYELOPROLIFERATIVE DISORDER; PATIENT COUNSELING; PRACTICE GUIDELINE; PREGNANCY COMPLICATION; PRIORITY JOURNAL; REVIEW; SPONTANEOUS ABORTION; THROMBOCYTHEMIA; THROMBOCYTOSIS; THROMBOSIS; FETOPLACENTAL UNIT; FETUS WASTAGE; HIGH RISK PATIENT; PATHOPHYSIOLOGY; RISK FACTOR; STILLBIRTH;

EID: 0037642297     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6926(03)00019-7     Document Type: Review

References (75)

1. Buss DH et al. Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases. American Journal of Medicine 1994; 96: 247-253.
2. 9/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. British Journal of Haematology 1998; 100: 15-23.
3. Regev A et al. Thrombotic complications in essential thrombocythaemia with relatively low platelet counts. American Journal of Hematology 1997; 56: 168-172.
4. Rozman C et al. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991; 67: 2658-2663.
5. Tefferi A et al. A long-term retrospective study of young women with essential thrombocythaemia. Mayo Clinic Proceedings 2001; 76: 22-28.
6. Fenaux P et al. Clinical course of essential thrombocythaemia in 147 cases. Cancer 1990; 66: 549-556.
7. Besses C et al. Major vascular complications in essential thrombocythaemia: a study of the predictive factors in a series of 148 patients. Leukemia 1999; 13: 150-154.
8. Ruggeri M et al. No treatment for low-risk thrombocythaemia: results from a prospective study. British Journal of Haematology 1998; 103: 772-777.
9. Cortelazzo S et al. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythaemia. Journal of Clinical Oncology 1990; 8: 556-562.
10. Cortelazzo S et al. Hydroxyurea for patients with essential thrombocythaemia and a high risk of thrombosis. New England Journal of Medicine 1995; 332: 1132-1136.
11. Tefferi A & Murphy S. Current opinion in essential thrombocythaemia: pathogenesis, diagnosis, and management. Blood Rev 2001; 15: 121-131.
12. Willoughby S & Pearson TC. The use of aspirin in polycythaemia vera and primary thrombocythaemia. Blood Rev 1998; 12: 12-22.
13. Buss DH, Stuart JJ & Lipscomb GE. The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases. American Journal of Hematology 1985; 20: 365-372.
14. van Genderen PJ & Michiels JJ. Erythromelalgic, thrombotic and haemorrhagic manifestations of thrombocythaemia. Presse Medicale 1994; 23: 73-77.
15. Schafer Al. Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984; 64: 1-12.
16. Finazzi G, Budde U & Michiels JJ. Bleeding time and platelet function in essential thrombocythaemia and other myeloproliferative syndromes. Leukemia & Lymphoma 1996; 22(supplement 1): 71-78.
17. Budde U et al. Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood 1984; 64: 981-985.
18. Budde U et al. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood 1993; 82: 1749-1757.
19. van Genderen PJ et al. Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythaemia: relationship with platelet count. Annals of Hematology 1994; 69: 81-84.
20. Vantroyen B & Vanstraelen D. Management of essential thrombocythaemia during pregnancy with aspirin, interferon alpha-2a and no treatment. A comparative analysis of the literature. Acto Haematologica 2002; 107: 158-169.
21. Griesshammer M, Heimpel H & Pearson TC. Essential thrombocythaemia and pregnancy. Leukemia & Lymphoma 1996; 22(supplement 1): 57-63.
22. Zahner J, Wehmeier A & Schneider W. Pregnancy in essential thrombocythaemia. Manifestation time and risk for mother and child. Dtsch Med Wochenschr 1995; 120: 1517-1523.
23. Beard J et al. Primary thrombocythaemia in pregnancy. British Journal of Haematology 199 1; 77: 371-374.
24. Beressi AH et al. Outcome analysis of 34 pregnancies in women with essential thrombocythaemia. Archives of Internal Medicine 1995; 155: 1217-1222.
25. Pagliaro P et al. Primary thrombocythaemia and pregnancy: treatment and outcome in fifteen cases. American Journal of Hematology 1996; 53: 6-10.
26. Randi ML et al. Essential thrombocythaemia in young adults: treatment and outcome of 16 pregnancies. Journal of Internal Medicine 1999; 246: 517-518.
27. Cincotta R et al. Management of essential thrombocythaemia during pregnancy. Australia & New Zealand Journal of Obstetrics & Gynaecology 2000; 40: 33-37.
28. Bangerter M et al. Pregnancy in essential thrombocythaemia: treatment and outcome of 17 pregnancies. European Journal of Haematology 2000; 65: 165-169.
29. Candoni A et al. Pregnancy and abortion in women with essential thrombocythaemia. American Journal of Hematology 2002; 69: 233-234.
30. Hatasaka HH. Recurrent miscarriage: epidemiologic factors, definitions, and incidence. Clinical Obstetrics & Gynecology 1994; 37: 625-634.
31. Cook CL & Pridham DD. Recurrent pregnancy loss. Current Opinion in Obstetrics & Gynecology 1995; 7: 357-366.
32. Martinelli I et al. Mutations in coagulation factors in women with unexplained late fetal loss. New England Journal of Medicine 2000; 343: 1015-1018.
33. Avigdor S, du Rouchet E & Body G. Essential thrombocythaemia and pregnancy. A review of the literature. J Gynecol Obstet Biol Reprod 1993; 22: 635-639.
34. Pardini S et al. Alpha 2b-interferon therapy and pregnancy-report of a case of essential thrombocythaemia. American Journal of Hematology 1993; 43: 78-79.
35. Pineo GF & Blahey WB. Essential thrombocythaemia and complications of pregnancy. American Journal of Hematology 1991; 36: 221.
36. Falconer J et al. Essential thrombocythaemia associated with recurrent abortions and fetal growth retardation. American Journal of Hematology 1987; 25: 345-347.
37. Snethlage W & Ten Cate JW. Thrombocythaemia and recurrent late abortions: normal outcome of pregnancies after antiaggregatory treatment. Case report. British Journal of Obstetrics & Gynaecology 1986; 93: 386-388.
38. Zoller B et al. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-3523.
39. Brenner B. Inherited thrombophilia and fetal loss. Current Opinion in Hematology 2000; 7: 290-295.
40. Pitkin RM & Witte DL. Platelet and leukocyte counts in pregnancy. JAMA 1979; 242: 2696-2698.
41. Sejeny SA, Eastham RD & Baker SR. Platelet counts during normal pregnancy. Journal of Clinical Pathology 1975; 28: 812-813.
42. Cairns JW et al. Platelet levels in pregnancy. Journal of Clinical Pathology 1977; 30: 392.
43. Chow EY, Haley LP & Vickars L.M. Essential thrombocythaemia in pregnancy: platelet count and pregnancy outcome. American Journal of Hematology 1992; 41: 249-251.
44. Wright CA & Tefferi A. A single institutional experience with 43 pregnancies in essential thrombocythaemia. European Journal of Haematology 200 1; 66: 152-159.
45. Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999; 353: 1258-1265.
46. Shih LY et al. Predictive values of X-chromosome inactivation patterns and clinicohematologic parameters for vascular complications in female patients with essential thrombocythaemia. Blood 2002; 100: 1596-1601.
47. van Genderen PJ et al. The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count. British Journal of Haematology 1996; 93: 962-965.
48. Doll DC, Ringenberg QS & Yarbro JW. Antineoplastic agents and pregnancy. Seminars in Oncology 1989; 16: 337-346.
49. Asano Y & Okaniwa A. In utero morphological effects of hydroxyurea on the fetal development in Sprague-Dawley rats. Jikken Dobutsu 1987; 36: 143-149.
50. Diav-Citrin O et al. Hydroxyurea use during pregnancy: a case report in sickle cell disease and review of the literature. American Journal of Hematology 1999; 60: 148-150.
51. Tefferi A et al. Anagrelide as a new platelet-lowering agent in essential thrombocythaemia: mechanism of actin, efficacy, toxicity, current indications. Seminars in Thrombosis & Hemostasis 1997; 23: 379-383.
52. Storen EC & Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythaemia. Blood 2001; 97: 863-866.
53. Waysbort A et al. Experimental study of transplacental passage of alpha interferon by two assay techniques. Antimicrobial Agents & Chemotherapy 1993; 37: 1232-1237.
54. Petit JJ, Callis M & Fernandez de Sevilla A. Normal pregnancy in a patient with essential thrombocythaemia treated with interferon-alpha 2b. American Journal of Hematology 1992; 40: 80.
55. Vianelli N et al. Interferon-alpha 2a treatment in a pregnant woman with essential thrombocythaemia. Blood 1994; 83: 874-875.
56. Thornley S & Manoharan A. Successful treatment of essential thrombocythaemia with alpha interferon during pregnancy. European Journal of Haematology 1994; 52: 63-64.
57. Perez-Encinas M et al. Familial myeloproliferative syndrome. American Journal of Hematology 1994; 46: 225-229.
58. Williams JM, Schlesinger PE & Gray AG. Successful treatment of essential thrombocythaemia and recurrent abortion with alpha interferon. British Journal of Haematology 1994; 88: 647-648.
59. Delage R et al. Treatment of essential thrombocythaemia during pregnancy with interferon-alpha. Obstetrics & Gynecology 1996; 87: 814-817.
60. Shpilberg O et al. Transient normal platelet counts and decreased requirement for interferon during pregnancy in essential thrombocythaemia. British Journal of Haemotology 1996; 92: 491-493.
61. Pulik M et al. Platelet counts during pregnancy in essential thrombocythaemia treated with recombinant alpha-interferon. British Journal of Haematology 1996; 93: 495.
62. Diez-Martin JL, Banas MH & Fernandez MN. Childbearing age patients with essential thrombocythaemia: should they be placed on interferon? American Journal of Hematology 1996; 52: 331-332.
63. Schmidt HH et al. Treatment of essential thrombocythaemia during pregnancy: antiabortive effect of interferon-alpha? Annals of Hematology 1998; 77: 291-292.
64. Taft EG et al. Plateletpheresis in the management of thrombocytosis. Blood 1977; 50: 927-933.
65. Mercer B et al. Primary thrombocythaemia in pregnancy: a report of two cases. American Journal of Obstetrics & Gynecology 1988; 159: 127-128.
66. Randi ML et al. Essential thrombocythaemia and pregnancy: a report of six normal pregnancies in five untreated patients. Obstetrics & Gynecology 1994; 83: 915-917.
67. Michiels JJ. Erythromelalgia and thrombocythaemia: a disease of platelet prostaglandin metabolism-thesis, Rotterdam, 1981. Seminars in Thrombosis & Hemostasis 1997; 23: 335-338.
68. Michiels JJ et al. Transient neurologic and ocular manifestations in primary thrombocythaemia. Neurology 1993; 43: 1107-1110.
69. van Genderen PJ, Leenknegt H & Michiels JL. The paradox of bleeding and thrombosis in thrombocythaemia: is von Willebrand factor the link? Seminars in Thrombosis & Hemostasis 1997; 23: 385-389.
70. van Genderen PJ et al. Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: normalization after cytoreduction of the increased platelet count. British Journal of Haematology 1997; 99: 832-836.
71. van Genderen PJ et al. Excessive prolongation of the bleeding time by aspirin in essential thrombocythaemia is related to a decrease of large von Willebrand factor multimers in plasma. Annals of Hematology 1997; 75: 215-220.
72. Rai R et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). British Medical Journal 1997; 314: 253-257.
73. Kutteh WH. Antiphospholipid anti body-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. American Journal of Obstetrics & Gynecology 1996; 174: 1584-1589.
74. Kupferminc MJ et al. Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias. Hypertens Pregnancy 200 1; 20: 35-44.
75. Brenner B et al. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thrombosis & Haemostasis 2000; 83: 693-697.